Thymidine phosphorylase to dihydropyrimidine dehydrogenase ratio as a predictive factor of response to preoperative chemoradiation with capecitabine in patients with advanced rectal cancer

Journal of Surgical Oncology

Volumn 102, Issue 5, 2010, Pages 408-412

  Boskos, C S ^a,b   Liacos, C ^c   Korkolis, D ^a   Aygerinos, K ^d   Lamproglou, I ^e   Terpos, E ^b   Stoupa, E ^b   Baltatzis, G ^a   Beroukas, K ^a   Papasavvas, P ^b   Dimopoulos, M A ^c   Bamias, A ^c  

^a Agios Savvas Anticancer Institute   (Greece)

^b 251 General Hellenic Airforce Hospital   (Greece)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^d Konstantopouleion Hospital Agia Olga   (Greece)

^e PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Capecitabine; Chemoradiation; Dihydropyrimidine dehydrogenase (DPD); Rectal cancer; Thymidine phosphorylase (TP)

Indexed keywords

BIOLOGICAL MARKER; CAPECITABINE; DIHYDROPYRIMIDINE DEHYDROGENASE; THYMIDINE PHOSPHORYLASE; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; FLUOROURACIL;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; DRUG RESPONSE; FEMALE; HUMAN; MALE; PREDICTOR VARIABLE; PREOPERATIVE RADIOTHERAPY; PRIORITY JOURNAL; RADIATION DOSE; RECTUM CANCER; TREATMENT RESPONSE; ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ANALOGS AND DERIVATIVES; CANCER STAGING; ENZYMOLOGY; METABOLISM; MIDDLE AGED; PATHOLOGY; PREOPERATIVE CARE; RECTAL NEOPLASMS; TREATMENT OUTCOME; YOUNG ADULT;

ADENOCARCINOMA; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CHEMOTHERAPY, ADJUVANT; DEOXYCYTIDINE; DIHYDROURACIL DEHYDROGENASE (NADP); FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PREOPERATIVE CARE; RADIATION DOSAGE; RADIOTHERAPY, ADJUVANT; RECTAL NEOPLASMS; THYMIDINE PHOSPHORYLASE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77957375100     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21423     Document Type: Article

References (44)

1. Janjan NA, Khoo VS, Abbruzzese J, et al.: Tumor downstaging and sphincter preservation with preoperative chemoradiation in locally advanced rectal cancer: The M.D. Anderson Cancer Center experience. Int J Radiat Oncol Biol Phys 1999;44:1027-1038. (Pubitemid 29342903)
2. Grann A, Minsky BD, Cohen AM, et al.: Preliminary results of preoperative 5-fluorouracil, low-dose leucovorin, and concurrent radiation therapy for clinically resectable T3 rectal cancer. Dis Colon Rectum 1997;40:515-522. (Pubitemid 27200688)
3. Korkolis DP, Boskos CS, Plataniotis GD, et al.: Pre-operative chemoradiotherapy with oral capecitabine in locally advanced, resectable rectal cancer. Anticancer Res 2007;27:541-545. (Pubitemid 46374974)
4. Valentini V, Coco C, Cellini N, et al.: Preoperative chemoradiation for extraperitoneal T3 rectal cancer: Acute toxicity, tumor response, and sphincter preservation. Int J Radiat Oncol Biol Phys 1998;40:1067-1075. (Pubitemid 28152921)
5. Wagman R, Minsky BD, Cohen AM, et al.: Sphincter preservation in rectal cancer with preoperative radiation therapy and coloanal anastomosis: Long term follow-up. Int J Radiat Oncol Biol Phys 1998;42:51-57. (Pubitemid 28435595)
6. Miwa M, Ura M, Nishida M, et al.: Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998;34:1274-1281. (Pubitemid 28342121)
7. Schüller J, Cassidy J, Dumont E, et al.: Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 2000;45:291-297. (Pubitemid 30151522)
8. Leichman CG, Lenz HJ, Leichman L, et al.: Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol 1997;15:3223-3229. (Pubitemid 27419335)
9. Metzger R, Danenberg K, Leichman CG, et al.: High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil. Clin Cancer Res 1998;4:2371-2376. (Pubitemid 28477901)
10. Popat S, Matakidou A, Houlston RS: Thymidylate synthase expression and prognosis in colorectal cancer: A systematic review and meta-analysis. J Clin Oncol 2004;22:529-536. Review. (Pubitemid 41079782)
11. Salonga D, Danenberg KD, Johnson M, et al.: Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 2000;6:1322-1327. (Pubitemid 30226214)
12. Nishida M, Hino A, Mori K, et al.: Preparation of anti-human thymidine phosphorylase monoclonal antibodies useful for detecting the enzyme levels in tumor tissues. Biol Pharm Bull 1996;19:1407-1411. (Pubitemid 26403242)
13. Ishikawa Y, Kubota T, Otani Y, et al.: Dihydropyrimidine dehydrogenase activity and messenger RNA level may be related to the antitumor effect of 5-fluorouracil on human tumor xenografts in nude mice. Clin Cancer Res 1999;5:883-889. (Pubitemid 29180841)
14. Nishimura G, Terada I, Kobayashi T, et al.: Thymidine phosphorylase and dihydropyrimidine dehydrogenase levels in primary colorectal cancer show a relationship to clinical effects of 5′-deoxy-5-fluorouridine as adjuvant chemotherapy. Oncol Rep 2002;9:479-482.
15. Morita T, Matsuzaki A, Tokue A: Quantitative analysis of thymidine phosphorylase and dihydropyrimidine dehydrogenase in renal cell carcinoma. Oncology 2003;65:125-131. (Pubitemid 37025973)
16. Mamounas E,Wieand S,Wolmark N, et al.: Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: Results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol 1999;17:1349-1355.
17. Sauer R, Fietkau R, Wittekind C, et al.: German Rectal Cancer Group. Adjuvant vs. neoadjuvant radiochemotherapy for locally advanced rectal cancer: The German trial CAO/ARO/AIO-94. Colorectal Dis 2003;5:406-415.
18. Hyams DM, Mamounas EP, Petrelli N, et al.: A clinical trial to evaluate the worth of preoperative multimodality therapy in patients with operable carcinoma of the rectum: A progress report of National Surgical Breast and Bowel Project Protocol R-03. Dis Colon Rectum 1997;40:131-139. (Pubitemid 27074280)
19. Schmoll HJ, Tabernero J, Nowacki M, et al.: Early safety findings from the phase III trial of capecitabine plus oxaloplatin (XELOX) vs. bolus 5-FU/LV as adjuvant therapy for patients with stage III colon cancer. SCO 2005, abstract No: 3523).
20. André T, Boni C, Mounedji-Boudiaf L, et al.: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:2343-2351. (Pubitemid 38702845)
21. Sebag-Montefiore D, Glynne-Jones R, Falk S, et al.: A phase I/II study of oxaliplatin when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: A Colorectal Clinical Oncology Group (CCOG) study. Br J Cancer 2005;93:993-998. (Pubitemid 41548392)
22. Glynne-Jones R, Sebag-Montefiore D, Maughan TS, et al.: A phase I dose escalation study of continuous oral capecitabine in combination with oxaliplatin and pelvic radiation (XELOX-RT) in patients with locally advanced rectal cancer. Ann Oncol 2006;17:50-56. Epub 2005 Nov 10. (Pubitemid 43033839)
23. Kim JC, Kim TW, Kim JH, et al.: Preoperative concurrent radiotherapy with capecitabine before total mesorectal excision in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2005;63:346-353. (Pubitemid 41317150)
24. Carmichael J, Popiela T, Radstone D, et al.: Randomized Comparative Study of Tegafur/Uracil and Oral Leucovorin Versus Parenteral Fluorouracil and Leucovorin in Patients With Previously Untreated Metastatic Colorectal Cancer. J Clin Oncol 2002;20:3617-3627. (Pubitemid 34983221)
25. Twelves C, Boyer M, Findlay M, et al.: Capecitabine (Xeloda™) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma. Eur J Cancer 2001;37:597-604. (Pubitemid 32261017)
26. Cox J, Pazdur R, Thibault A, et al.: A Phase III trial of Xeloda® (capecitabine) in previously untreated advanced/metastatic colorectal cancer. Proc Am Soc Clin Oncol 1999;18:A1016.
27. Ishii R, Takiguchi N, Oda K, et al.: Thymidine phosphorylase expression is useful in selecting adjuvant chemotherapy for stage III gastric cancer. Int J Oncol 2001;19:717-722.
28. Konno S, Takebayashi Y, Aiba M, et al.: Clinicopathological and prognostic significance of thymidine phosphorylase and proliferating cell nuclear antigen in gastric carcinoma. Cancer Lett 2001;166:103-111. (Pubitemid 32274291)
29. Maeda K, Chung YS, Takatsuka S, et al.: Tumor angiogenesis as a predictor of recurrence in gastric carcinoma. J Clin Oncol 1995;13:477-481.
30. Takebayashi Y, Aklyama S, Yamada K, et al.: Angiogenesis as an unfavorable prognostic factor in human colorectal carcinoma. Cancer 1996;78:226-231. (Pubitemid 26234563)
31. Ogawa K, Konno S, Takebayashi Y, et al.: Clinicopathological and prognostic significance of thymidine phosphorylase expression in gastric carcinoma. Anticancer Res 1999;19:4363-4367. (Pubitemid 30042791)
32. Matsuura T, Kuratate I, Teramachi K, et al.: Thymidine phosphorylase expression is associated with both increase of intratumoral microvessels and decrease of apoptosis in human colorectal carcinomas. Cancer Res 1999;59:5037-5040. (Pubitemid 29472912)
33. Kitazono M, Takebayashi Y, Ishitsuka K, et al.: Prevention of hypoxia-induced apoptosis by the angiogenic factor thymidine phosphorylase. Biochem Biophys Res Commun 1998;253:797-803. (Pubitemid 29039222)
34. Katsumata K, Sumi T, Yamashita S, et al.: The significance of thymidine phosphorylase expression in colorectal cancer. Oncol Rep 2001;8:127-130. (Pubitemid 33758214)
35. Nagata T, Nakamori M, Iwahashi M, et al.: Overexpression of pyrimidine nucleoside phosphorylase enhances the sensitivity to 5′-deoxy-5- fluorouridine in tumour cells in vitro and in vivo. Eur J Cancer 2002;38:712-717. (Pubitemid 34251396)
36. Jakob C, Aust DE, Meyer W, et al.: Thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase expression, and histological tumour regression after 5-FU-based neo-adjuvant chemoradiotherapy in rectal cancer. J Pathol 2004;204:562-568. (Pubitemid 39585955)
37. Hayashi T, Kawahara H, Kobayashi S, et al.: Importance of thymidine phosphorylase, dihydropyrimidine dehydrogenase and thymidylate synthase expression at the invasive front of T3 rectal cancer as prognostic factors. Hepatogastroenterology 2008;55:403-406. (Pubitemid 351741470)
38. Kocakova I, Svoboda M, Kubosova K, et al.: Preoperative radiotherapy and concomitant capecitabine treatment induce thymidylate synthase and thymidine phosphorylase mRNAs in rectal carcinoma. Neoplasma 2007;54:447-453.
39. Tominaga T, Toi M, Ohashi Y, et al.: Prognostic and predictive value of thymidine phosphorylase activity in early-stage breast cancer patients. Clin Breast Cancer 2002;3:55-64. (Pubitemid 34546073)
40. Lu ZH, Zhang R, Diasio RB: Purification and characterization of dihydropyrimidine dehydrogenase from human liver. J Biol Chem 1992;267:17102-17109.
41. Johnson MR,Wang K, Tillmanns S, et al.: Structural organization of the human dihydropyrimidine dehydrogenase gene. Cancer Res 1997;57:1660-1663. (Pubitemid 27199654)
42. Harris BE, Song R, Soong SJ, et al.: Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 1990;50:197-201. (Pubitemid 20030018)
43. Lyss AP, Lilenbaum RC, Harris BE, et al.: Severe 5-fluorouracil toxicity in a patient with decreased dihydropyrimidine dehydrogenase activity. Cancer Invest 1993;11:239-240. (Pubitemid 23105044)
44. Etienne MC, Chéradame S, Fischel JL, et al.: Response to fluorouracil therapy in cancer patients: The role of tumoral dihydropyrimidine dehydrogenase activity. J Clin Oncol 1995;13:1663-1670.